Argenx
ARGX
#522
Rank
A$63.41 B
Marketcap
A$1,025
Share price
-1.01%
Change (1 day)
12.70%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): A$13.55

According to Argenx 's latest financial reports the company's current EPS (TTM) is A$12.36. In 2024 the company made an earnings per share (EPS) of A$19.40 an increase over its 2023 EPS that were of A-$7.19.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$13.55-30.18%
2024A$19.40-369.77%
2023A-$7.19-60.46%
2022A-$18.1963.33%
2021A-$11.14-40.37%
2020A-$18.68183.47%
2019A-$6.59123.09%
2018A-$2.9554.93%
2017A-$1.9114.07%
2016A-$1.6713.05%
2015A-$1.48-36.34%
2014A-$2.32209.04%
2013A-$0.75-33.99%
2012A-$1.14185.59%
2011A-$0.40